NCT03966079View on ClinicalTrials.gov

Thrombolysis Endovascular Treatment of Pulmonary Embolism

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Pulmonary EmbolismAcute Pulmonary Embolism
Interventions
DRUG

recombinant tissue plasminogen activator

Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter

Trial Locations (1)

102218

Beijing Tsinghua Chang Gung Hospital, Beijing

All Listed Sponsors
lead

Beijing Tsinghua Chang Gung Hospital

OTHER

NCT03966079 - Thrombolysis Endovascular Treatment of Pulmonary Embolism | Biotech Hunter | Biotech Hunter